Fibrocell Science (FCSC) Stock Price, News & Analysis

Company Overview

Fibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was incorporated in 1992 and is based in Exton, Pennsylvania.

Key Stats

• Today's Range: $3.00 to $3.00
• 50-Day Range: $3.00 to $3.00
• 52-Week Range: $1.45 to $3.28
• Volume: N/A
• Average Volume: 78,673 shs
• Market Capitalization: $29.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

FCSC Stock Analysis - Frequently Asked Questions

How were Fibrocell Science's earnings last quarter?

Fibrocell Science Inc (NASDAQ:FCSC) posted its quarterly earnings data on Wednesday, August, 14th. The company reported $1.12 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $1.30. The firm had revenue of $21.79 million for the quarter.

When did Fibrocell Science's stock split?

Fibrocell Science shares reverse split before market open on Friday, May 25th 2018. The 1-5 reverse split was announced on Thursday, May 24th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 24th 2018. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

What other stocks do shareholders of Fibrocell Science own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Fibrocell Science investors own include The Carlyle Group (CG), Celldex Therapeutics (CLDX), Neos Therapeutics (NEOS), Amarin (AMRN), OPKO Health (OPK), Neurotrope (NTRP) and Sorrento Therapeutics (SRNE).

Company Calendar

• Last Earnings: 8/14/2019
• Today: 11/21/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:FCSC
• CUSIP: N/A
• CIK: 357097
• Web: fibrocell.com
• Phone: 484-713-6000
• Fax: N/A
• Employees: 19
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 30.00
• P/E Growth: N/A
• Net Income: $-10,280,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: 23.10%
• Return on Assets: 10.56%

Debt

• Debt-to-Equity Ratio: 0.47
• Current Ratio: 5.09
• Quick Ratio: 5.09

Sales & Book Value

• Annual Sales: $350,000.00
• Price / Sales: 83.66
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.98 per share
• Price / Book: 3.06

Miscellaneous

• Outstanding Shares: 9,760,000
• Free Float: N/A
• Market Cap: $29.28 million
• Optionable: Optionable
• Beta: 1.67